<DOC>
	<DOCNO>NCT00998296</DOCNO>
	<brief_summary>The primary objective trial determine Maximum Tolerated Dose ( MTD ) combination BIBW 2992/BIBF 1120 therapy administer concomitantly . The MTD provide dose recommendation subsequent phase II trial patient metastatic cancer .</brief_summary>
	<brief_title>Phase I Dose Escalation Study Concomitant BIBF 1120 BIBW 2992 Patients With Advanced Solid Tumours .</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients confirm histological cytological diagnosis advance solid tumour proven therapy exist amenable establish treatment . 2 . Age 18 year old . 3 . Life expectancy least three month . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 5 . Patients previously treat asymptomatic brain metastasis eligible 6 . Patients must recover recent surgery . Exclusion criterion : 1 . Active infectious disease 2 . Recent surgery within last 4 week prior visit 1 . 3 . Chronic diarrhoea gastrointestinal tract disease result inability take oral medication 4 . History haemorrhagic thrombotic event 5 . Significant cardiovascular disease within 6 . Current peripheral neuropathy &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 except due trauma 7 . Untreated symptomatic brain metastasis leptomeningeal disease . 8 . Treatment Epidermal growth Factorreceptor ( EGFR ) Heregulin Receptor 2 ( HER2 ) inhibit drug antiangiogenic drug . 9 . Therapeutic anticoagulation . 10 . Female patient childbearing potential . 11 . Known preexist interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>